biostudies-literatureJoseph JNational Center for Advancing Translational SciencesNCATS NIH HHSNIA NIH HHSNIDDK NIH HHSNHLBI NIH HHSHSRD VANational Institute on AgingCSRD VA1701-1713https://www.ebi.ac.uk/biostudies/studies/S-EPMC10258159biostudies-literatureUnknown71(6)Whether initiation of statins could increase survival free of dementia and disability in adults aged ≥75 years is unknown. PREVENTABLE, a double-blind, placebo-controlled randomized pragmatic clinical trial, will compare high-intensity statin therapy (atorvastatin 40 mg) with placebo in 20,000 community-dwelling adults aged ≥75 years without cardiovascular disease, disability, or dementia at baseline. Exclusion criteria include statin use in the prior year or for >5 years and inability to take a statin. Potential participants are identified using computable phenotypes derived from the electronic health record and local referrals from the community. Participants will undergo baseline cognitive testing, with physical testing and a blinded lipid panel if feasible. Cognitive testing and disabiJournal of the American Geriatrics SocietyPragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale.PMC10258159U19 AG065188R01 HL155396P30 DK092986IK2 CX001800R01 AG058883I01 HX003518UL1 TR001863P30 AG028716U24 TR001608P30 AG021332U24TR001608I01 CX000570P30 AG021342R01 AG060499R01 AG071807P30 AG072947Young ATaylor ZPREVENTABLE Trial Research GroupVanterpool YEGonzalez MWharton JThiel RCarrillo MYurko EKirchner KTaylor CRubin CPatel MBah HHervey JHall MFisher AMarkland AVenetucci JHenrie AMHeimberg MReboussin DZeng AGaziano MHouston DWilliams SAlred CSnyder HBeaverson BPeruvemba SGreenland PGrieshaber VShivaswamy VLower EWhite JMassey JSpreyer KSawyer LLinares VSpencer AKHalverson KHall DOwens ACicek MBazzano LWall MCripps SSachs BGrdinovac KTapan MNewby LKRapp SGill TMCooper-DeHoff RMRomashkan SRao SSt John MBowman JTamariz LLinder JBenziger CPCarlsson CBloodworth SAshley NSchmader KECarrasquillo OThompson GBerendt MChamberlain AMBinder EVanWormer JJGupta ACarlson MReynolds JRubinstein JVaughan CPKohnhorst DOu JNauman BHunt DRao GGazmuri RJDavis DChatterjee RWells BReuben DRothman RBunke JReuben-Hallock KPeek BTavabi ALoepfe TAmbrosius WTAlmonte AAlmonte JWhittle JCFernandes JHufstedler MCastle TWaitman RAkatue RJones SKiran SJohnson KLiu MHoutschilt SMusi NPangle ARamalingam RPeduzzi PSullivan DShah RCZylstra HBoyer LKirke STodela TMunoz ABordelon LHahn-Cover KRomero IRoumie CLFine LCooper-DeHoff RKitzman HHernandez AFWalsh JHart JKitzman DYaksic ERicks JKnowlton KUAlbert MBrill SEffron MBFlorez HKistler CEHetzel JUfholz KBreitner JCardoso ELeverty RNulph RJefferson MDecker JEAke JGordon HMonds PHoisington KThongsa SCallahan KMcTique KPajewski NMHammill BGWhite SMPahor MKapitanovsky KGodschalk MEspique LTravison TDolor RJRodriguez-Cintron WRosas SSolomon SAlexander KPPeeples SRHy CPenny WDavies IChoudhary GClarke JAKramer HLee PSellers MAKulshreshtha ARives ELee JOberembt SAzhar GBancks MLee CChang ADohner CChau KAtlas SShade LOrkaby ARVu KPerdue LHWithee CEspinoza SBrashears BMixon ASTenorio JWeiner MLorscheter JRichmond AAllen JDruckrey JRicci AKelsey MJindra MSupiano MAWoolard NBurnet KLaffey MKaczkowski KMichael JKnipping VZamora ESoe KGoyal PForman DEGuerrero RBSingh VPark FGaussoin SLowe TStrout KWillis TDeckard NLu JKansal MWhiteside HTinker AWilliamson JDShapiro MDVanDoren KPolonsky TSLockhart MChildress RKlawson EBetancourt JTelzak AKaseno JZieman SRunge CGauvey-Kern MBatch BKing MNewman AErnst MCarton TMeilander ALovato LFuentes-Medina SWing JLovato JJones WSKirkwood LEleazer PShenkman BKrishnasamy SCicek MSJoseph JDenizard JBrown KHallock AMalm BBrown WLang SFord DWilliams NABrown TPoddar KKundu SfalsePragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale.Whether initiation of statins could increase survival free of dementia and disability in adults aged ≥75 years is unknown. PREVENTABLE, a double-blind, placebo-controlled randomized pragmatic clinical trial, will compare high-intensity statin therapy (atorvastatin 40 mg) with placebo in 20,000 community-dwelling adults aged ≥75 years without cardiovascular disease, disability, or dementia at baseline. Exclusion criteria include statin use in the prior year or for >5 years and inability to take a statin. Potential participants are identified using computable phenotypes derived from the electronic health record and local referrals from the community. Participants will undergo baseline cognitive testing, with physical testing and a blinded lipid panel if feasible. Cognitive testing and disabi2023-01-01T00:00:00Z2023 Jun2026-06-03T06:46:48.854Z2026-05-29T03:05:55.072ZS-EPMC102581593708280710.1111/jgs.18312